New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer

References

• ShibuyaKMathersCDBoschi-PintoCLopezADMurrayCJGlobal and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000BMC Cancer200223712502432
   PubMed Web of Science ®Google Scholar
• LynchTJBellDWSordellaRActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med2004350212129213915118073
   PubMed Web of Science ®Google Scholar
• PaezJGJannePALeeJCEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience200430456761497150015118125
   PubMed Web of Science ®Google Scholar
• SodaMChoiYLEnomotoMIdentification of the transforming EML4-ALK fusion gene in non-small-cell lung cancerNature2007448715356156617625570
   PubMed Web of Science ®Google Scholar
• KwakELCamidgeDRClarkJClinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066J Clin Oncol200927Suppl Abstract 3509
   Google Scholar
• ArdiniEMagnaghiPOrsiniPGalvaniAMenichincheriMAnaplastic Lymphoma Kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapyCancer Lett20102992819420934803
   PubMed Web of Science ®Google Scholar
• GrandeEBolósMVArriolaETargeting oncogenic ALK: a promising strategy for cancer treatmentMol Cancer Ther201110456957921474455
   PubMed Web of Science ®Google Scholar
• DeuelTFAnaplastic lymphoma kinase: “Ligand Independent Activation” mediated by the PTN/RPTPβ/ζ signaling pathwayBiochim Biophys Acta20131834102219222323777859
   PubMed Web of Science ®Google Scholar
• MoranTQuirogaVde los Llanos GilMTargeting EML4-ALK driven non-small cell lung cancer (NSCLC)Transl Lung Cancer Res20132212814125806224
   PubMedGoogle Scholar
• SolomonBVarella-GarciaMCamidgeDRALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancerJ Thorac Oncol20094121450145420009909
   PubMed Web of Science ®Google Scholar
• TakeuchiKChoiYLTogashiYKIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancerClin Cancer Res20091593143314919383809
   PubMed Web of Science ®Google Scholar
• RikovaKGuoAZengQGlobal survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancerCell200713161190120318083107
   PubMed Web of Science ®Google Scholar
• TakeuchiKChoiYLSodaMMultiplex reverse transcription-PCR screening for EML4-ALK fusion transcriptsClin Cancer Res200814206618662418927303
   PubMed Web of Science ®Google Scholar
• ShawATKimDWNakagawaKCrizotinib versus chemotherapy in advanced ALK-positive lung cancerN Engl J Med2013368252385239423724913
   PubMed Web of Science ®Google Scholar
• MurakamiYMitsudomiTYatabeYA screening method for the ALK fusion gene in NSCLCFront Oncol201222422655265
   PubMedGoogle Scholar
• ConklinCMCraddockKJHaveCLaskinJCoutureCIonescuDNImmunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependentJ Thorac Oncol2013814551
   PubMed Web of Science ®Google Scholar
• MincaECPortierBPWangZALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISHJ Mol Diagn201315334134623499337
   PubMed Web of Science ®Google Scholar
• MartinezPHernández-LosaJMonteroMÁFluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patientsPLoS One201381e5226123359795
   PubMed Web of Science ®Google Scholar
• ParkHSLeeJKKimDWImmunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patientsLung Cancer201277228829222465695
   PubMed Web of Science ®Google Scholar
• ShollLMWeremowiczSGraySWCombined use of ALK immunohistochemistry and FISH for optimal detection of ALK- rearranged lung adenocarcinomasJ Thorac Oncol20138332232823407557
   PubMed Web of Science ®Google Scholar
• ShawATYeapBYMino-KenudsonMClinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALKJ Clin Oncol200927264247425319667264
   PubMed Web of Science ®Google Scholar
• PaikJHChoiCMKimHClinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinomaLung Cancer201276340340922129856
   PubMed Web of Science ®Google Scholar
• KwakELBangYJCamidgeDRAnaplastic lymphoma kinase inhibition in non-small-cell lung cancerN Engl J Med2010363181693170320979469
   PubMed Web of Science ®Google Scholar
• KrisMGJohnsonBEKwiatkowskiDJIdentification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC)J Clin Oncol201129Suppl Abstract CRA7506
   Google Scholar
• HornLPaoWEML4-ALK: honing in on a new target in non-small-cell lung cancerJ Clin Oncol200927264232423519667260
   PubMed Web of Science ®Google Scholar
• LindemanNICaglePTBeasleyMBMolecular testing guideline for selection of lung cancer patients for egfr and alk tyrosine kinase inhibitors: summary of recommendations [webpage on the Internet]International Association for the Study of Lung Cancer (IASLC)2013 Available at https://www.iaslc.org/sites/default/files/wysiwyg-assets/cap_iaslc_amp_summary_of_recommendations.pdfAccessed May 22, 2014
   Google Scholar
• GridelliCPetersSSgambatoACasaluceFAdjeiAACiardielloFALK inhibitors in the treatment of advanced NSCLCCancer Treat Rev201440230030623931927
   PubMed Web of Science ®Google Scholar
• CuiJJTran-DubéMShenHStructure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)J Med Chem201154186342636321812414
   PubMed Web of Science ®Google Scholar
• ZouHYLiQLeeJHAn orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanismsCancer Res20076794408441717483355
   PubMed Web of Science ®Google Scholar
• CamidgeDRBangYJKwakELActivity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 studyLancet Oncol201213101011101922954507
   PubMed Web of Science ®Google Scholar
• RielyGJEvansTLSalgiaRResults of a global phase II study of crizotinib in advanced ALK-positive non-small cell lung cancerPresented at the IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology 2012September 6–8, 2012 Abstract 166
   Google Scholar
• GiacconeGWangYStrategies for overcoming resistance to EGFR family tyrosine kinase inhibitorsCancer Treat Rev201137645646421367530
   PubMed Web of Science ®Google Scholar
• DeiningerMBuchdungerEDrukerBJThe development of imatinib as a therapeutic agent for chronic myeloid leukemiaBlood200510572640265315618470
   PubMed Web of Science ®Google Scholar
• SequistLVWaltmanBADias-SantagataDGenotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsSci Transl Med201137575ra26
   PubMed Web of Science ®Google Scholar
• ChoiYLSodaMYamashitaYALK Lung Cancer Study GroupEML4-ALK mutations in lung cancer that confer resistance to ALK inhibitorsN Engl J Med2010363181734173920979473
   PubMed Web of Science ®Google Scholar
• KatayamaRKhanTMBenesCTherapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALKProc Natl Acad Sci U S A2011108187535754021502504
   PubMed Web of Science ®Google Scholar
• SakamotoHTsukaguchiTHiroshimaSCH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutantCancer Cell201119567969021575866
   PubMed Web of Science ®Google Scholar
• DoebeleRCPillingABAisnerDLMechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancerClin Cancer Res20121851472148222235099
   PubMed Web of Science ®Google Scholar
• MehraRCamidgeDRSharmaSFirst-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumorsJ Clin Oncol201230Suppl Abstract 3007
   Google Scholar
• ShawATMehraMKimD-WClinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLCJ Clin Oncol201331Suppl Abstract 8010
   Google Scholar
• ShawATKimDWMehraRCeritinib in ALK-rearranged non-small-cell lung cancerN Engl J Med2014370131189119724670165
   PubMed Web of Science ®Google Scholar
• ShawATMokTSpigelDRA phase II single-arm study of LDK378 in patients with ALK-activated (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ)J Clin Oncol201331Suppl Abstract TPS8119
   Google Scholar
• KiuraKSetoTYamamotoNA first-in-human phase I/II study of ALK inhibitor CH5424802 in patients with ALK-positive NSCLCJ Clin Oncol201230Suppl Abstract 7602
   Google Scholar
• NakagawaKKiuraKNishioMA phase I/II study with a highly selective ALK inhibitor CH5424802 in ALK-positive non-small cell lung cancer (NSCLC) patients: Updated safety and efficacy results from AF-001JPJ Clin Oncol201331Suppl Abstract 8033
   Google Scholar
• GadgeelSOuSHChiapporiAA phase I dose escalation study of a new ALK inhibitor, SH542480202, in ALK + non-small cell lung cancer patients who have failed crizotinibPresented at the 15th World Conference on Lung CancerOctober 27–30, 2013Sydney, Australia Abstract O16.06
   Google Scholar
• OuSHGadgeelSChiapporiAAConsistent therapeutic efficacy of CH5424802/RO5424802 in brain metastases among crizotinib-refractory ALK-positive non-small cell lung cancer (NSCLC) patients in an ongoing phase I/II studyPresented at the 15th World Conference on Lung CancerOctober 27–30, 2013Sydney, Australia10292013 Abstract O16.07
   Google Scholar
• CamidgeDRBazhenovaLSalgiaRFirst-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated resultsJ Clin Oncol201331Suppl Abstract 8031
   Google Scholar
• TrepelJMollapourMGiacconeGNeckersLTargeting the dynamic HSP90 complex in cancerNat Rev Cancer201010853754920651736
   PubMed Web of Science ®Google Scholar
• SangJAcquavivaJFriedlandJCTargeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancerCancer Discov20133443044323533265
   PubMed Web of Science ®Google Scholar
• SequistLVGettingerSSenzerNNActivity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancerJ Clin Oncol201028334953496020940188
   PubMed Web of Science ®Google Scholar
• CrinoLKimDRielyGJInitial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): Profile 1005J Clin Oncol201129Suppl Abstract 7514
   PubMed Web of Science ®Google Scholar
• SnyderCFBlackfordALOkuyamaTUsing the EORTC-QLQ-C30 in clinical practice for patient management: identifying scores requiring a clinician’s attentionQual Life Res201322102685269123532341
   PubMed Web of Science ®Google Scholar
• BergmanBAaronsonNKAhmedzaiSKaasaSSullivanMThe EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of LifeEur J Cancer199430A56356428080679
   PubMed Web of Science ®Google Scholar
• ChinLAndersenJNFutrealPACancer genomics: from discovery science to personalized medicineNat Med201117329730321383744
   PubMed Web of Science ®Google Scholar
• GandhiLJännePACrizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new targetClin Cancer Res201218143737374222547770
   PubMed Web of Science ®Google Scholar